HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Padgett, D. A. Articles by Sheridan, J. F. Articles citing this Article PubMed PubMed Citation Articles by Padgett, D. A. Articles by Sheridan, J. F.

Androstenediol-Induced Restoration of Responsiveness to Influenza Vaccination in Mice

^a Section of Oral Biology, College of Social and Behavioral Sciences,
^b Department of Psychology, College of Social and Behavioral Sciences,
^c Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond,
^d Institute for Behavioral Medicine Research, Ohio State University, Columbus

David A. Padgett, Box 192, Postle Hall, 305 West 12th Avenue, Columbus, OH 43210 E-mail: padgett.11{at}osu.edu.

Jay Roberts, PhD

Androstenediol (AED), a metabolite of dehydroepiandrosterone (DHEA) regulates innate and adaptive immune responses. To examine whether AED could effectively reverse the age-associated decline of antiviral immunity, 3-, 10-, and 22-month-old mice were treated with AED-sulfate (AED-S) for 45 days beginning 10 days prior to vaccination. Subsequently, mice were primed and boosted with suboptimal doses of a commercially-available trivalent influenza vaccine. Treatment of 10-month-old animals with AED-S during vaccination increased the titer of circulating antiviral immunoglobulin G to levels comparable with those in 3-month-old mice. Furthermore, AED-S treatment protected 10-month-old animals from intranasal challenge with a lethal dose of influenza virus 21 days after secondary vaccination. Although AED-S treatment of 22-month-old mice did not enhance vaccine responses and failed to protect against lethal challenge, the data from the 10-month-old animals suggest that treatment with AED-S will prevent the early manifestations of immunosenescence.